vs

Side-by-side financial comparison of Adaptive Biotechnologies Corp (ADPT) and AlTi Global, Inc. (ALTI). Click either name above to swap in a different company.

AlTi Global, Inc. is the larger business by last-quarter revenue ($86.6M vs $70.9M, roughly 1.2× Adaptive Biotechnologies Corp). Adaptive Biotechnologies Corp runs the higher net margin — 4.7% vs -15.1%, a 19.9% gap on every dollar of revenue. On growth, AlTi Global, Inc. posted the faster year-over-year revenue change (87.0% vs 35.1%). Over the past eight quarters, AlTi Global, Inc.'s revenue compounded faster (30.6% CAGR vs 28.1%).

ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.

Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.

ADPT vs ALTI — Head-to-Head

Bigger by revenue
ALTI
ALTI
1.2× larger
ALTI
$86.6M
$70.9M
ADPT
Growing faster (revenue YoY)
ALTI
ALTI
+51.9% gap
ALTI
87.0%
35.1%
ADPT
Higher net margin
ADPT
ADPT
19.9% more per $
ADPT
4.7%
-15.1%
ALTI
Faster 2-yr revenue CAGR
ALTI
ALTI
Annualised
ALTI
30.6%
28.1%
ADPT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ADPT
ADPT
ALTI
ALTI
Revenue
$70.9M
$86.6M
Net Profit
$3.4M
$-13.1M
Gross Margin
73.6%
Operating Margin
-27.1%
-2.1%
Net Margin
4.7%
-15.1%
Revenue YoY
35.1%
87.0%
Net Profit YoY
75.6%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ADPT
ADPT
ALTI
ALTI
Q1 26
$70.9M
Q4 25
$71.7M
$86.6M
Q3 25
$94.0M
$57.2M
Q2 25
$58.9M
$53.1M
Q1 25
$52.4M
$58.0M
Q4 24
$47.5M
$46.3M
Q3 24
$46.4M
$51.8M
Q2 24
$43.2M
$49.5M
Net Profit
ADPT
ADPT
ALTI
ALTI
Q1 26
$3.4M
Q4 25
$-13.6M
$-13.1M
Q3 25
$9.5M
$-84.1M
Q2 25
$-25.6M
$-24.4M
Q1 25
$-29.9M
$1.9M
Q4 24
$-33.7M
$-53.8M
Q3 24
$-32.1M
$-72.5M
Q2 24
$-46.2M
$-6.4M
Gross Margin
ADPT
ADPT
ALTI
ALTI
Q1 26
73.6%
Q4 25
74.6%
Q3 25
80.7%
Q2 25
69.4%
Q1 25
67.6%
Q4 24
62.0%
Q3 24
64.1%
Q2 24
55.3%
Operating Margin
ADPT
ADPT
ALTI
ALTI
Q1 26
-27.1%
Q4 25
-17.8%
-2.1%
Q3 25
10.9%
-49.8%
Q2 25
-42.5%
-56.7%
Q1 25
-56.4%
-23.3%
Q4 24
-71.3%
-42.7%
Q3 24
-70.3%
-18.4%
Q2 24
-109.6%
-30.2%
Net Margin
ADPT
ADPT
ALTI
ALTI
Q1 26
4.7%
Q4 25
-18.9%
-15.1%
Q3 25
10.2%
-147.0%
Q2 25
-43.5%
-45.9%
Q1 25
-56.9%
3.3%
Q4 24
-71.0%
-116.1%
Q3 24
-69.1%
-140.0%
Q2 24
-107.0%
-12.9%
EPS (diluted)
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
$-0.08
Q3 25
$0.06
Q2 25
$-0.17
$-0.33
Q1 25
$-0.20
$-0.04
Q4 24
$-0.22
$-0.71
Q3 24
$-0.22
$-0.88
Q2 24
$-0.31
$-0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ADPT
ADPT
ALTI
ALTI
Cash + ST InvestmentsLiquidity on hand
$77.6M
$41.2M
Total DebtLower is stronger
$883.0K
Stockholders' EquityBook value
$600.1M
Total Assets
$505.9M
$1.2B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ADPT
ADPT
ALTI
ALTI
Q1 26
$77.6M
Q4 25
$70.5M
$41.2M
Q3 25
$55.0M
$35.8M
Q2 25
$43.2M
$42.4M
Q1 25
$50.6M
$52.8M
Q4 24
$47.9M
$64.4M
Q3 24
$38.1M
$220.6M
Q2 24
$59.8M
$60.0M
Total Debt
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
$883.0K
Q3 25
$586.0K
Q2 25
$673.0K
Q1 25
Q4 24
$0
Q3 24
$128.4M
Q2 24
$164.0M
Stockholders' Equity
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
$218.8M
$600.1M
Q3 25
$204.4M
$607.2M
Q2 25
$179.7M
$685.4M
Q1 25
$190.4M
$665.2M
Q4 24
$202.7M
$658.4M
Q3 24
$223.8M
$707.0M
Q2 24
$241.6M
$540.2M
Total Assets
ADPT
ADPT
ALTI
ALTI
Q1 26
$505.9M
Q4 25
$512.7M
$1.2B
Q3 25
$490.6M
$1.2B
Q2 25
$496.6M
$1.2B
Q1 25
$510.9M
$1.2B
Q4 24
$539.4M
$1.3B
Q3 24
$558.5M
$1.4B
Q2 24
$584.9M
$1.3B
Debt / Equity
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
Q4 24
0.00×
Q3 24
0.18×
Q2 24
0.30×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ADPT
ADPT
ALTI
ALTI
Operating Cash FlowLast quarter
$-51.4M
Free Cash FlowOCF − Capex
$-52.2M
FCF MarginFCF / Revenue
-60.3%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
$2.1M
$-51.4M
Q3 25
$-7.1M
$-53.5M
Q2 25
$-12.4M
$-19.9M
Q1 25
$-28.5M
$-30.2M
Q4 24
$-12.5M
$-50.7M
Q3 24
$-27.1M
$-4.9M
Q2 24
$-17.3M
$-30.2M
Free Cash Flow
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
$1.4M
$-52.2M
Q3 25
$-7.5M
Q2 25
$-13.1M
$-20.0M
Q1 25
$-29.7M
$-31.0M
Q4 24
$-12.6M
$-58.2M
Q3 24
$-27.4M
$-9.4M
Q2 24
$-19.0M
$-31.2M
FCF Margin
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
2.0%
-60.3%
Q3 25
-8.0%
Q2 25
-22.2%
-37.6%
Q1 25
-56.7%
-53.4%
Q4 24
-26.5%
-125.7%
Q3 24
-59.0%
-18.2%
Q2 24
-44.1%
-63.2%
Capex Intensity
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
0.9%
0.9%
Q3 25
0.4%
0.0%
Q2 25
1.1%
0.0%
Q1 25
2.4%
1.3%
Q4 24
0.2%
16.3%
Q3 24
0.7%
8.7%
Q2 24
4.0%
2.2%
Cash Conversion
ADPT
ADPT
ALTI
ALTI
Q1 26
Q4 25
Q3 25
-0.75×
Q2 25
Q1 25
-15.80×
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ADPT
ADPT

Segment breakdown not available.

ALTI
ALTI

Management Advisory Fees$51.1M59%
Other$32.7M38%
Distributions From Investments$2.9M3%

Related Comparisons